Écrit par VEXIM | 26 Septembre 2014

Perspectives

Accélération du développement aux États-Unis avec un lancement commercial dans la vertébroplastie et cyphoplastie prévu au début de 2015

 

Toulouse, le 22 septembre 2014 - VEXIM (FR0011072602 - ALVXM / éligible PEA-PME), société de dispositifs médicaux spécialisée dans le traitement mini-invasif des fractures vertébrales, annonce aujourd'hui ses résultats...

Écrit par Wiley | 17 Septembre 2014

In a new study of cancer patients who smoke, those using e-cigarettes (in addition to traditional cigarettes) were more nicotine dependent and equally or less likely to have quit smoking traditional cigarettes than non-users. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings raise doubts about the potential benefits of e-cigarettes for...

Écrit par Novartis | 16 Septembre 2014

Brain shrinkage is associated with a loss of physical and cognitive function and occurs at a faster rate in people with MS than those without the disease

New data showed patients who had the highest rates of brain shrinkage (brain volume loss) at two years had a higher risk of disability progression at four years

Separate analyses showed that patients continuously treated with Gilenya...

Écrit par Novartis | 16 Septembre 2014

A key treatment goal for patients with MS is ‘no evidence of disease activity’ (NEDA), currently defined as no relapses, MRI lesions and disability progression

Including MS-related brain shrinkage (brain volume loss) as a fourth key measure captures underlying damage that begins early in MS and is associated with loss of function

The likelihood of achieving NEDA across four key...